Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)

Bibliography

• Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373(9680):2055-66
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6
   PubMed Web of Science ®Google Scholar
• Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006;116(7):1744-54
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339(15):1044-53
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339(16):1130-43
   PubMed Web of Science ®Google Scholar
• Hardy J, Lewis P, Revesz T, The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 2009;19(3):254-65
   Google Scholar
• Schulte C, Gasser T. Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. Appl Clin Genet 2011;4:67-80
   PubMedGoogle Scholar
• Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;2:R183-94
   Google Scholar
• Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet 2011;12:301-25
   PubMed Web of Science ®Google Scholar
• Dächsel JC, Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol 2010;67(5):542-7
   PubMedGoogle Scholar
• Anand VS, Braithwaite SP. LRRK2 in Parkinson's disease: biochemical functions. FEBS J 2009;276(22):6428-35
   Google Scholar
• Biskup S, West AB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 2009;1792(7):625-33
   Google Scholar
• Healy DG, Falchi M, O'Sullivan SS, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7(7):583-90
   PubMed Web of Science ®Google Scholar
• Smith WW, Pei Z, Jiang H, Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9(10):1231-3
   Google Scholar
• West AB, Moore DJ, Biskup S, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005;102(46):16842-7
   PubMed Web of Science ®Google Scholar
• Smith WW, Pei Z, Jiang H, Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005;102(51):18676-81
   PubMed Web of Science ®Google Scholar
• Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009;1(1):e00002
   PubMedGoogle Scholar
• Kumar A, Cookson MR. Role of LRRK2 kinase dysfunction in Parkinson disease. Expert Rev Mol Med 2011;13:e20
   PubMed Web of Science ®Google Scholar
• Novartis A.-G., Switz. Dihydroindole derivatives useful in parkinson's disease patent. WO2009030270A1; 2009
   Google Scholar
• Anand VS, Reichling LJ, Lipinski K, Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. FEBS J 2009;276(2):466-78
   Google Scholar
• Nichols RJ, Dzamko N, Hutti JE, Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 2009;424(1):47-60
   PubMedGoogle Scholar
• Lee BD, Shin JH, VanKampen J, Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010;16(9):998-1000
   PubMed Web of Science ®Google Scholar
• The Johns Hopkins University, USA. LRRK2-mediated neuronal toxicity patent. WO2011057204A2; 2011
   Google Scholar
• Krug M, Hilgeroth A. Recent advances in the development of multi-kinase inhibitors. Mini Rev Med Chem 2008;8(13):1312-27
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Padhani A, Hayes C, A phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer 2005;93(8):876-83
   Google Scholar
• Spiekermann K, Faber F, Voswinckel R, The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 2002;30(7):767-73
   Google Scholar
• Sessa C, Vigano L, Grasselli G, Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 2006;42(2):171-8
   Google Scholar
• Karaman MW, Herrgard S, Treiber DK, A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-32
   PubMed Web of Science ®Google Scholar
• Davis MI, Hunt JP, Herrgard S, Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011;29(11):1046-51
   PubMed Web of Science ®Google Scholar
• Moore WJ, Richard D, Thorarensen A. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola. Expert Opin Ther Patents 2010;20(12):1703-22
   PubMed Web of Science ®Google Scholar
• Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357(3):258-65
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27(19):3126-32
   PubMed Web of Science ®Google Scholar
• Cellzome Ltd, UK. Preparation of substituted pyrimidinediamines as LRRK2 inhibitors for treating neurodegenerative diseases patent. WO2009127642A2; 2009
   Google Scholar
• Cellzome A.-G., Germany. Method for the identification of an LRRK2 (leucine-rich repeat kinase 2)-interacting compound patent. WO2007104763A1; 2007
   Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25(9):1035-44
   PubMed Web of Science ®Google Scholar
• Ramsden N, Perrin J, Ren Z, Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol 2011;6(10):1021-8
   PubMed Web of Science ®Google Scholar
• Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 2008;7(5):391-7
   PubMed Web of Science ®Google Scholar
• Deng X, Dzamko N, Prescott A, Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 2011;7(4):203-5
   PubMed Web of Science ®Google Scholar
• Dana Farber Cancer Institute, USA. Preparation of pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders patent. WO2010080712A2; 2010
   Google Scholar
• Bain J, Plater L, Elliott M, The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408(3):297-315
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Szardenings AK, Liyanage M, Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 2007;46(2):350-8
   PubMed Web of Science ®Google Scholar
• Dzamko N, Deak M, Hentati F, Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 2010;430(3):405-13
   PubMedGoogle Scholar
• Nichols RJ, Dzamko N, Morrice NA, 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 2010;430(3):393-404
   PubMed Web of Science ®Google Scholar
• Galkin AV, Melnick JS, Kim S, Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104(1):270-5
   PubMed Web of Science ®Google Scholar
• Zhang J, Deng X, Choi HG, Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett 2012;22(5):1864-9
   PubMed Web of Science ®Google Scholar
• Deng X, Wang J, Zhang J, Discovery of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors. ACS Med Chem Lett 2011;2(5):379-84
   Google Scholar
• Choi HG, Zhang J, Deng X, Brain penetrant LRRK2 Inhibitor. ACS Med Chem Lett 2012;3(8):658-62
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-La Roche AG, Switz. Aminopyrimidine derivatives as LRRK2 modulators and their preparation and use for the treatment of Parkinson's disease patent. WO2011151360A1; 2011
   Google Scholar
• Madoux F, Li X, Chase P, Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening. Mol Pharmacol 2008;73(6):1776-84
   Google Scholar
• Chen H, Chan BK, Drummond J, Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. J Med Chem 2012;55(11):5536-45
   PubMed Web of Science ®Google Scholar
• Genosco, USA; Oscotec, Inc. Protein Kinase inhibitors patent. WO2011053861A1; 2011
   Google Scholar
• Available from: http://www.genosco.com/LRRK2.pdf
   Google Scholar
• Aventis Pharma S.A., Fr. Preparation of substituted pyrazolopyridines as kinase inhibitors, and their compositions and use for treatment of cancer patent. WO2006077319A1; 2006
   Google Scholar
• Intellikine, Inc., USA. Preparation of pyrazolopyridines as protein and lipid kinase inhibitors patent. WO2009114870A2; 2009
   Google Scholar
• Bristol-Myers Squibb Co., USA. Azaindazoles as Btk kinase modulators and their preparation patent. WO2011019780A1; 2011
   Google Scholar
• Medical Research Council Technology, UK. Preparation of pyrazolopyridine compounds as kinase inhibitors patent. WO2010106333A1; 2010
   Google Scholar
• Medical Research Council Technology, UK. Preparation of pyrazolopyridines as kinase LRRK2 inhibitors for treating and preventing cancer and neurodegenerative diseases patent. WO2011141756A1; 2011
   Google Scholar
• Wager TT, Hou X, Verhoest PR, Moving beyond rules: the development of a Central Nervous System Multiparameter Optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010;1:435-49
   PubMed Web of Science ®Google Scholar
• Glaxo Group Ltd, UK; Glaxosmithkline China R&D Co., Ltd. N-Aryl and N-heteroaryl benzyloxybenzamide derivatives as LRRK2 inhibitors and their preparation and use for the treatment of Parkinson's disease patent. WO2011038572A1; 2011
   Google Scholar
• Liechti C, Sequin U, Bold G, Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. Eur J Med Chem 2004;39:11-26
   Google Scholar
• Reith AD, Bamborough P, Jandu K, GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg Med Chem Lett 2012;22(17):5625-9
   PubMed Web of Science ®Google Scholar
• Liu G, Aliaga L, Cai H. Alpha-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol 2012;7(2):145-53
   Google Scholar
• Greggio E, Jain S, Kingsbury A, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23(2):329-41
   PubMed Web of Science ®Google Scholar
• Herzig MC, Kolly C, Persohn E, LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 2011;20(21):4209-23
   PubMed Web of Science ®Google Scholar
• Tong Y, Yamaguchi H, Giaime E, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 2010;107(21):9879-84
   PubMed Web of Science ®Google Scholar